Lymph node ratio provides prognostic information in addition to american joint committee on cancer N stage in patients with melanoma, even if quality of surgery is standardized

Annals of Surgery

Volumn 253, Issue 1, 2011, Pages 109-115

  Spillane, Andrew J ^a,b,c,d,e   Cheung, Bernard L H ^d   Winstanley, Julie ^a,b   Thompson, John F ^a,b,c,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b MELANOMA INSTITUTE AUSTRALIA   (Australia)

^c Mater Hospital   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; DEMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MELANOMA; MITOSIS RATE; PRIORITY JOURNAL; PROGNOSIS; STANDARDIZATION; SURGEON; TUMOR LOCALIZATION; TUMOR VOLUME;

AGED; AXILLA; COHORT STUDIES; FEMALE; GROIN; HEAD AND NECK NEOPLASMS; HUMANS; LYMPH NODE EXCISION; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE;

EID: 78751629245     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181f9b8b6     Document Type: Article

References (19)

1. Truong PT, Vinh-Hung V, Cserni G, et al. The number of positive nodes and the ratio of positive to excised nodes are significant predictors of survival in women with micrometastatic node-positive breast cancer. Eur J Cancer. 2008;44(12):1670-1677.
2. Gajra A, Newman N, Gamble GP, et al. Effect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancer. J Clin Oncol. 2003;21(6):1029-1034.
3. Wang J, Hassett JM, Dayton MT, et al. Lymph node ratio: role in the staging of node-positive colon cancer. Ann Surg Oncol. 2008;15(6):1600-1608.
4. Bollschweiler E, Baldus SE, Schroder W, et al. Staging of esophageal carcinoma: length of tumor and number of involved regional lymph nodes. Are these independent prognostic factors? J Surg Oncol. 2006; 94(5):355-363.
5. Coburn NG, Swallow CJ, Kiss A, et al. Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer. Cancer. 2006;107(9):2143-2151.
6. Xing Y, Badgwell BD, Ross MI, et al. Lymph node ratio predicts disease-specific survival in melanoma patients. Cancer. 2009;115(11): 2505-2513.
7. Rossi CR, Mocellin S, Pasquali S, et al. N-ratio: a novel independent prognostic factor for patients with stage-III cutaneous melanoma. Ann Surg Oncol. 2008;15(1):310-315.
8. Galliot-Repkat C, Cailliod R, Trost O, et al. The prognostic impact of the extent of lymph node dissection in patients with stage III melanoma. Eur J Surg Oncol. 2006;32(7):790-794.
9. Spillane AJ, Winstanley J, Thompson JF. Lymph node ratio in melanoma: a marker of variation in surgical quality? Cancer. 2009;115(11):2384-2387.
10. vanAkkooi A, Wilt JD, Verhoef C, et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol 2006; 17:1578-1585.
11. NCCN. NCCN Clinical Practice Guidelines in Oncology. Melanoma v.2.2008. National Comprehensive Cancer Network, 2008. http://www.nccn.org/professionals/ physician-gls/PDF/melanoma.pdf
12. Thompson J, Morton D, Kroon B. Textbook of Melanoma., Vol. 1. London and New York: Martin Dunitz; 2004.
13. Balch CM, Durant JR, Bartolucci AA. The impact of surgical quality control in multi-institutional group trials involving adjuvant cancer treatments. Ann Surg. 1983;198(2):164-167.
14. Morton D. Study Protocol: Multicenter Selective Lymphadenectomy Trial II (MSLT II): A phase III multicenter randomized trial of sentinel lymphadenec-tomy and complete lymph node dissection versus sentinel lymphadenec-tomy alone in cutaneous melanoma patients with molecular or histopatho-logical evidence of metastases in the sentinel node. John Wayne Cancer Institute 2004. http://clinicaltrials.gov/ct/show/NCT00297895
15. Spillane AJ, Cheung BL, Stretch JR, et al. Proposed quality standards for regional lymph node dissections in patients with melanoma. Ann Surg. 2009;249(3):473-480.
16. AJCC. American Joint Committee Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag, 2002.
17. Smalley KS, Flaherty KT. Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment. Future Oncol. 2009;5(6):775-778.
18. Hughes TM, A'Hern RP, Thomas JM. Prognosis and surgical management of patients with palpable inguinal lymph node metastases from melanoma. Br J Surg. 2000;87(7):892-901.
19. Ung O, Tan M, Chua B, Barraclough B. Complete axillary dissection: a technique that still has relevance in contemporary management of breast cancer. ANZ J Surg. 2006;76(6):518-521.